ReferencesDormandy, J. A., Charbonnel, B., Eckland, D. J. A.et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279–89.
Higgs, E. R., and Krentz, A. J. (2004) Association of British Clinical Diabetologists position statement on glitazones. Practical Diabetes International 21: 1–3.
Holman, R. R., Cull, C. A. and Turner, R. C. (1999) A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 22: 960–4.
Khan, S. E., Haffner, S. M., Heise, M. A.et al. (2006) Glycaemic durability of rosiglitazone, metformin or glyburide monotherapy. New England Journal of Medicine 355: 2427–43.
Nathan, D. M., Buse, J. B., Davidson, M. B.et al. (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 49: 1711–21.
Nissan, S. E., and Wolski, K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 356: 2457–71.
,Nutrition Committee of the Diabetes Care Advisory Committee of Diabetes UK (2003) The implementation of nutritional advice for people with diabetes. Diabetic Medicine 20: 786–807.
Schwartz, A. V., and Sellmeyer, D. E. (2007) Thiazolidinedione therapy gets complicated. Is bone loss the price of improved insulin resistance?Diabetes Care 30: 1670–71.
Stratton, I. M., Adler, A. I., Neil, H. A.et al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal 321: 405–12.
,UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with diabetes (UKPDS 34). Lancet 352: 854–65.
